香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而産生或因依賴該等內容而 引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：01898） 召開2025年半年度業績説明會 中國中煤能源股份有限公司（「本公司」）擬於2025年8月22日（星期五）刊發截至2025年6月30日止 六個月之半年度業績公告。為了便於廣大投資者更加全面瞭解本公司2025年半年度業績和經營情況， 本公司擬於2025年8月25日（星期一）15:30-16:30以電話會議、視頻直播和網絡互動方式舉行2025年半 年度業績說明會（「業績說明會」）。本公司將針對2025年半年度業績和經營情況，在信息披露允許 的範圍內就投資者普遍關注的問題進行交流。本公司執行董事、總裁，獨立非執行董事，首席財務 官，副總裁，董事會秘書及有關部門負責人將出席業績説明會。 投資者屆時可以通過上證路演中心網站（http://roadshow.sseinfo.com/roadshowList.do）或「進門財經」 網站（https:/ ...

Group 1 - The Energy ETF (159930) opened with a gain of 0.59%, priced at 1.369 yuan [1] - Major holdings in the Energy ETF include China Shenhua, which rose by 10.01%, while China Petroleum fell by 0.12% [1] - The ETF's performance benchmark is the CSI Energy Index, managed by Huatai-PineBridge Fund Management Co., Ltd., with a return of 36.12% since its inception on August 23, 2013, and a return of 4.40% over the past month [1] Group 2 - Other notable stock movements include China Petrochemical rising by 0.18%, Shaanxi Coal and Chemical Industry increasing by 1.07%, and Yanzhou Coal Mining up by 1.00% [1] - The ETF also saw gains from Jereh Oilfield Services (0.96%), China Coal Energy (1.15%), Shanxi Coking Coal (0.14%), and Meijin Energy (1.31%) [1]

丨证券研究报告丨 行业研究丨点评报告丨煤炭与消费用燃料 [Table_Title] 7 月统计局数据点评 ——原煤产量同比转负，旺季火电增幅扩大 报告要点 [Table_Summary] 展望后市：1）动力煤：随着高温天气继续推升日耗刺激电厂采购需求释放，及后续"金九银十" 非电旺季有望维持用电韧性，或为动力煤价持续上行带来期待，后续关注产地超产核查情况、 高温天气催化及终端需求释放持续性，考虑到当前煤炭红利板块依旧低配，股息率性价比较高， 防御配置价值凸显。2）焦煤：超产管控、阅兵前安监偏严及部分矿井自发实行"276"限产共同 使得供给整体偏紧，铁水高位震荡下终端用煤刚需有支撑但采购需求或阶段性放缓，短期焦煤 价格或趋稳运行，在政策预期催化及中报利空释放后有望博弈焦煤阶段性配置机会。 分析师及联系人 [Table_Author] SAC：S0490516080003 SAC：S0490519030001 SAC：S0490517070008 SAC：S0490522090003 SAC：S0490524120007 SFC：BUT918 SFC：BUY139 肖勇 赵超 叶如祯 庄越 韦思宇 请阅读最后评级 ...

丨证券研究报告丨 行业研究丨行业周报丨煤炭与消费用燃料 [Table_Title] 钢铁限产，焦煤价格就一定回落吗？ 报告要点 [Table_Summary] 近期钢铁限产预期增强，市场普遍担忧钢铁限产往往会导致焦煤需求回落，从而抑制焦煤价格。 然而历史上来看并非如此：由于钢铁行政性限产往往引发钢厂利润快速修复，因此减弱了钢厂 对上游原材料的压价意愿，最终形成钢焦共振上涨格局，权益端也存在绝对收益；然而若钢铁 因亏损较多而导致自发性减产，则钢焦价格往往共振回落，权益端表现同样较差。展望 2025 年，当前钢厂利润依旧较优，自发性减产动力不足；若后续存行政性减产可能，有望使得钢焦 价格共振上涨，权益端也有望获得绝对收益。 分析师及联系人 [Table_Author] SAC：S0490516080003 SAC：S0490519030001 SAC：S0490517070008 SAC：S0490522090003 SAC：S0490524120007 SFC：BUT918 SFC：BUY139 肖勇 赵超 叶如祯 庄越 韦思宇 请阅读最后评级说明和重要声明 %% %% %% %% research.95579 ...

港口煤价突破 700 元/吨,神华复牌龙头价值不改 煤炭 证券研究报告/行业定期报告 2025 年 08 月 16 日 分析师: 杜冲 执业证书编号: S0740522040001 Email: duchong@zts.com.cn | 基本状况 | | | --- | --- | | 上市公司数 | 37 | | 行业总市值(亿元) | 17.844.03 | | 行业流通市值(亿元) | 17.446.59 | 行业-市场走势对比 相关报告 1、《"276工作日"生产自律再现, 煤炭供给收缩预期强化》2025-08-12 《供给收紧预期加深,煤价短期 2. 震荡偏强》2025-08-10 《短期基本面偏强,煤价升势料 3. 延续》 2025-08-03 | 重占公司甚本状况 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | | (元) | 2023A | ...

产量核查约束供给，非电需求韧性足 [Table_ReportTime] 2025 年 8 月 17 日 证券研究报告 行业研究-周报 [Table_ReportType] 行业周报 | [Table_StockAndRank] 煤炭开采 | | | --- | --- | | 投资评级 | 看好 | | 上次评级 | 看好 | 高升：煤炭钢铁行业首席分析师 执业编号：S1500524100002 邮箱：gaosheng@cindasc.com 李睿：煤炭钢铁行业分析师 执业编号：S1500525040002 邮箱：lirui@cindasc.com 刘波： 煤炭钢铁行业分析师 执业编号：S1500525070001 邮箱：liubo1@cindasc.com 信达证券股份有限公司 CINDASECURITIESCO.,LTD 北京市西城区宣武门西大街甲 127 号 金隅大厦 B 座 邮编：100031 [Table_Title] 产量核查约束供给，非电需求韧性足 [Table_ReportDate] 2025 年 8 月 17 日 本期内容提要: [Table_Summary] 请阅读最后一页免责声明及信息披 ...

Investment Rating - Maintain "Buy" rating for the coal mining industry [5] Core Viewpoints - The coal production in July 2025 reached a new low since May 2001, indicating a "reversal, not a rebound" in the market [1] - The report emphasizes that while coal production is expected to grow in 2025, the growth rate is projected to narrow to approximately 1.4% [1] - The report highlights the importance of government policies in stabilizing coal supply and prices, suggesting that recent measures could lead to a price bottoming out [4][33] Production Summary - In July 2025, the industrial raw coal production was 380 million tons, a year-on-year decrease of 3.8%, with a daily average production of 12.29 million tons [1][11] - For the first seven months of 2025, the total industrial raw coal production was 2.78 billion tons, showing a year-on-year increase of 3.8% [1][11] - The forecast for total thermal coal production in 2025 is around 3.88 billion tons, with a growth rate of 1.4% [1][11] Import Summary - In July 2025, coal imports were 35.609 million tons, a decrease of 22.9% compared to the same month last year [1][14] - For the first seven months of 2025, total coal imports were 257.305 million tons, reflecting a year-on-year decline of 13.0% [1][14] - The expected total thermal coal import level for 2025 is projected to be around 38 million tons, down 6.4% year-on-year [1][14] Demand Summary - In July 2025, the industrial power generation reached 926.7 billion kWh, a year-on-year increase of 3.1% [2][17] - The growth rate of industrial thermal power generation was 4.3%, accelerating by 3.2 percentage points compared to June [2][17] - Solar power generation saw a significant increase of 28.7% year-on-year, with a notable acceleration in growth [2][17] Investment Recommendations - The report suggests focusing on major coal enterprises such as China Shenhua and China Coal Energy, as well as companies with strong performance elasticity like Lu'an Mining and Jinneng Holding [4][33] - The report also highlights the potential of companies undergoing asset restructuring, such as Anyuan Coal Industry, and those with promising future growth like Huayang Co. and Gansu Energy [4][33]

Investment Rating - The industry rating is "Positive" [1] Core Viewpoints - Coal inventory has decreased year-on-year for the first time, indicating a continuous improvement in the fundamentals of the coal industry [1] - The coal sector has underperformed compared to the CSI 300 index, with a decline of 0.77% as of August 15, 2025, while the CSI 300 index rose by 2.37% [2] - Key monitored enterprises reported an average daily coal sales volume of 7.15 million tons, a week-on-week increase of 1.9% and a year-on-year increase of 5.3% [2] - The total coal inventory of key monitored enterprises was 26.18 million tons as of August 14, 2025, a week-on-week decrease of 5.9% and a year-on-year decrease of 3.1% [2] - The supply-demand balance in the coal market is improving, with significant price increases for thermal coal and potential marginal improvements in the coking coal sector due to environmental factors [6] Summary by Sections Thermal Coal Industry Chain - As of August 15, 2025, the price index for thermal coal (Q5500K) in the Bohai Rim was 670 CNY/ton, a week-on-week increase of 0.3% [3] - The average daily sales volume of thermal coal increased by 0.6% week-on-week [2] Coking Coal Industry Chain - The main coking coal price at Jingtang Port was 1,630 CNY/ton, unchanged week-on-week [4] - The inventory of coking coal at Jingtang Port decreased by 5.4% week-on-week [4] Coal Chemical Industry Chain - The price of methanol in East China was 2,354.55 CNY/ton, a week-on-week decrease of 38.86 CNY/ton [5] - The price of urea in Henan was 1,700 CNY/ton, a week-on-week decrease of 50 CNY/ton [5] Investment Recommendations - The report suggests focusing on high-dividend thermal coal companies and coking coal companies undergoing turnaround [6] - Key companies to watch include China Shenhua, Shaanxi Coal and Chemical Industry, and Yanzhou Coal Mining Company for thermal coal; and Huabei Mining, Shanxi Coking Coal, and Lu'an Environmental Energy for coking coal [6]

格隆汇8月14日丨中煤能源(601898.SH)公布7月份主要生产经营数据，商品煤销量2117万吨，同比下降 9.6%。 ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]